Combinations and uses thereof
US-2025195646-A1 · Jun 19, 2025 · US
This page is not indexed by search engines while we improve data quality.
Winderlich Mark patents
Winderlich Mark is listed as an inventor on 24 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Winderlich Mark |
| Total patents | 24 |
| First publication | Jan 15, 2015 |
| Latest publication | Jun 19, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
US-2025186460-A1 · Jun 12, 2025 · US
Combinations and uses thereof
US-12194095-B2 · Jan 14, 2025 · US
Combinations and uses thereof
US-2024424012-A1 · Dec 26, 2024 · US
Combinations and uses thereof
US-2024366756-A1 · Nov 7, 2024 · US
Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
US-2024009196-A1 · Jan 11, 2024 · US
Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
US-2022283166-A1 · Sep 8, 2022 · US
Anti-cd19 therapy in patients having a limited number of nk cells
US-2022242952-A1 · Aug 4, 2022 · US
Combinations and uses thereof
US-2022088197-A1 · Mar 24, 2022 · US
Combinations and uses thereof
US-11224654-B2 · Jan 18, 2022 · US
Recent patents
Latest publications not already listed above.
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
US-2021292410-A1 · Sep 23, 2021 · US
Combinations and uses thereof
US-2020352975-A1 · Nov 12, 2020 · US
Combinations and uses thereof
US-2020353077-A1 · Nov 12, 2020 · US
Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
US-2020206228-A1 · Jul 2, 2020 · US
Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
US-10617691-B2 · Apr 14, 2020 · US
Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
US-2019195879-A1 · Jun 27, 2019 · US
Method for the treament of multiple myeloma or non-hodgkins lymphoma with anti-CD38 antibody in combination with thalidomine, lenalidomids, or pomalidomide
US-10308722-B2 · Jun 4, 2019 · US
Combinations and uses thereof
US-2018228893-A1 · Aug 16, 2018 · US
Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
US-2018153892-A1 · Jun 7, 2018 · US
Method for the treatment of multiple myeloma or non-hodgkins lymphoma with anti-cd38 antibody and bortezomib or carfilzomib
US-2018022823-A1 · Jan 25, 2018 · US
Method for the treatment of multiple myeloma or non-Hodgkins lymphoma with anti-CD38 antibody and bortezomib or carfilzomib
US-9765152-B2 · Sep 19, 2017 · US
Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL
US-2016222127-A1 · Aug 4, 2016 · US
Combinations and uses thereof
US-9289490-B2 · Mar 22, 2016 · US
Combinations and uses thereof
US-2015017160-A1 · Jan 15, 2015 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Morphosys Ag | 19 |
| Incyte Corp | 5 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P35/00 | 22 |
| A61P35/02 | 22 |
| A61K39/3955 | 20 |
| A61K39/39558 | 17 |
| A61K2039/505 | 17 |